Tesaro (TSRO) Gets a Buy Rating from H.C. Wainwright


In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Tesaro (TSRO), with a price target of $69. The company’s shares closed on Friday at $46.38.

According to TipRanks.com, White is a 5-star analyst with an average return of 14.4% and a 43.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tesaro with a $49.73 average price target, a 7.2% upside from current levels. In a report issued on November 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $68 price target.

.

See today’s analyst top recommended stocks >>

Based on Tesaro’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $137 million. In comparison, last year the company had a GAAP net loss of $25.28 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts